Table 1 Clinicopathological characteristics of high- and low- Metadherin expression groups.

From: Bioinformatic analysis reveals an association between Metadherin with breast cancer prognosis and tumor immune infiltration

Characteristics

Low expression of MTDH

High expression of MTDH

P value

n

543

544

 

Pathologic T stage, n (%)

0.135

 T1

136 (12.5%)

142 (13.1%)

 

 T2

306 (28.2%)

325 (30%)

 

 T3

83 (7.7%)

57 (5.3%)

 

 T4

18 (1.7%)

17 (1.6%)

 

Pathologic N stage, n (%)

0.054

 N0

263 (24.6%)

253 (23.7%)

 

 N1

187 (17.5%)

172 (16.1%)

 

 N2

45 (4.2%)

71 (6.6%)

 

 N3

43 (4%)

34 (3.2%)

 

Pathologic M stage, n (%)

0.119

 M0

429 (46.4%)

476 (51.5%)

 

 M1

13 (1.4%)

7 (0.8%)

 

Pathologic stage, n (%)

0.432

 Stage I

95 (8.9%)

87 (8.2%)

 

 Stage II

315 (29.6%)

304 (28.6%)

 

 Stage III

117 (11%)

127 (11.9%)

 

 Stage IV

12 (1.1%)

6 (0.6%)

 

Race, n (%)

0.138

 Asian

33 (3.3%)

27 (2.7%)

 

 Black or African American

105 (10.5%)

77 (7.7%)

 

 White

376 (37.7%)

379 (38%)

 

Age, n (%)

0.978

  ≤ 60

301 (27.7%)

302 (27.8%)

 

  > 60

242 (22.3%)

242 (22.3%)

 

Histological type, n (%)

 < 0.001

 Infiltrating ductal carcinoma

331 (30.9%)

445 (41.6%)

 

 Infiltrating lobular carcinoma

149 (13.9%)

56 (5.2%)

 

 Mixed histology (please specify)

13 (1.2%)

16 (1.5%)

 

 Mucinous carcinoma

13 (1.2%)

4 (0.4%)

 

 Other, specify

27 (2.5%)

16 (1.5%)

 

PR status, n (%)

0.354

 Negative

163 (15.8%)

179 (17.3%)

 

 Positive

351 (33.9%)

341 (33%)

 

ER status, n (%)

0.425

 Negative

114 (11%)

126 (12.2%)

 

 Positive

402 (38.8%)

395 (38.1%)

 

HER2 status, n (%)

0.708

 Negative

277 (38.6%)

283 (39.5%)

 

 Positive

75 (10.5%)

82 (11.4%)

 

Menopause status, n (%)

0.314

 Pre

104 (10.7%)

126 (12.9%)

 

 Peri

20 (2%)

20 (2%)

 

 Post

360 (36.9%)

346 (35.5%)

 

OS event, n (%)

 < 0.001

 Alive

488 (44.9%)

447 (41.1%)

 

 Dead

55 (5.1%)

97 (8.9%)

 

DSS event, n (%)

0.025

 No

506 (47.4%)

476 (44.6%)

 

 Yes

33 (3.1%)

52 (4.9%)

 

PFI event, n (%)

0.135

 No

478 (44%)

462 (42.5%)

 

 Yes

65 (6%)

82 (7.5%)

 
  1. The Wilcoxon rank-sum test was used to analyze the data.